Overview
Nplex Biosciences develops proteomics tools using nanotechnology, with the nELISA platform that miniaturizes and parallelizes the sandwich ELISA to measure many proteins at once. The platform uses DNA nanotechnology to decode protein identities on micron-sized beads, enabling cost-efficient, high-throughput protein profiling. It differentiates itself by combining DNA-based protein identification with bead-based assays and a scalable workflow that lowers costs compared to traditional antibody-based proteomics. The goal is to provide a reliable, scalable proteomics platform that supports drug discovery, biomarker discovery, and personalized medicine.
Work here?Claim your company
Simplify's take
What believers are saying
- Nomic and Broad Clinical Labs target broader commercialization starting in early 2027.
- June 2026 Sanger and HESI OASIS collaborations expand high-value dataset generation.
- September 2024's $42 million Series B lifted total funding above $60 million.
What critics are saying
- Illumina bought SomaLogic in January 2026, strengthening a much larger proteomics rival.
- Olink and SomaLogic already own distribution, squeezing Nomic's pricing and sales cycles.
- If pharma adoption stalls before 2027, Nomic stays a niche services business.
What makes Nomic unique
- nELISA delivers 99.99% specificity and 0.1 pg/mL sensitivity at 1,000-plus samples daily.
- Omni 1000 packages 1,000 curated assays with absolute quantification for discovery workflows.
- Nature Methods publication and Nomic Portal datasets validate scalable protein profiling workflows.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards